This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.
- ACCRU SC-1601 EVE Trial
A randomized phase III trial studying the best dose of apixaban and how well it works in preventing secondary cancer related blood clots in cancer patients who have completed anticoagulation therapy.
A study in men with biochemically recurrent prostate cancer and PSA doubling time = 9 months at the time of study entry.
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS.
- Alliance 151216/ ALCHEMIST Alliance A081105, A081801 & ECOG E4512
The ALCHEMIST trials are testing therapies that target two types of genetic changes that are thought to drive lung cancer growth: mutations in the EGFR gene and a rearrangement of the ALK gene.
- Alliance A011401
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence).
- Alliance A021502
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.
- Alliance A021703 "SOLARIS"
This Alliance phase III trial looks at how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body.
- Alliance A031501
A trial studying how well pembrolizumab works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes.
- Alliance A031704 “PDIGREE”
A phase III trial in metastatic untreated renal cell cancer.